Download Sample
For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-cancer-tubulin-inhibitors-market-and-clinical-trial-insight-2024.php
Table of Contents
1. Microtubules – Moving Target in Cancer Therapy
1.1 Overview
1.2 Tubulin Inhibitors for Cancer Treatment
1.2.1 Microtubule Stabilizing Proteins
1.2.2 Microtubule Destabilizing Proteins
2. Mechanism of Action and Mechanism of Resistance of Tubulin Inhibitors
2.1 Mechanism of Action
2.2 Mechanism of Resistance to Microtubule Binding Agents
3. Microtubules and Their Role in Cellular Stress in Cancer
3.1 Tubulin Alterations in Cancer
3.1.1 Changes in Tubulin Isotype Composition
3.1.2 Tubulin Post Translational Modifications
3.1.3 Microtubule Associated Proteins (MAP)
3.2 Tubulin Cytoskeleton in Stress Response
4. Prognostic Role of Tubulin for Prediction of Cancer Aggressiveness
4.1 Non Small Cell Lung Cancer
4.2 Prostate Cancer
4.3 Breast Cancer
4.4 Colorectal Cancer
4.5 Ovarian Cancer
5. Price and Dosage Analysis of Tubulin Inhibitor Drugs
5.1 Docetaxel
5.2 Trastuzumab Emtansine
5.3 Abraxane
5.4 Brentuximab Vedotin
5.5 Cabazitaxel
6. Market Analysis of Tubulin Inhibitors
6.1 Overview
6.2 Global Sales of Tubulin Inhibitors Drugs
7. Global Cancer Tubulin Inhibitors Clinical Pipeline Overview
8. Global Cancer Tubulin Inhibitors Clinical Pipeline by Company and Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
9. Marketed Cancer Tubulin Inhibitors Clinical Insight
9.1 Docetaxel (Taxotere)
9.2 Trastuzumab Emtansine (Kadcyla)
9.3 Vinflunine (Javlor)
9.4 Albumin-Bound Paclitaxel (Abraxane and Coraxane)
9.5 Cabazitaxel (Jevtana)
9.6 Brentuximab Vedotin (Adcetris)
9.7 Paclitaxel Polymeric Micelle Formulation (Cynviloq and Genexol-PM)
9.8 Paclitaxel Liposomal – Sun Pharma Advanced Research Company
9.9 Paclitaxel Liposomal (Lipusu)
9.10 Paclitaxel Nanoparticle (Nanoxel)
10. Global Cancer Tubulin Inhibitors Market Dynamics
10.1 Favorable Market Parameters
10.2 Commercialization Challenges
11. Future Perspective of Cancer Tubulin Inhibitors
12. Competitive Landscape
12.1 Abraxis Biosciences
12.2 Agensys
12.3 Amgen
12.4 Celgene
12.5 Eagle Pharmaceuticals
12.6 Endocyte
12.7 Genentech
12.8 Immunogen
12.9 Modra Pharmaceuticals
12.10 Pierre Fabre
12.11 Roche
12.12 Sanofi-Aventis
12.13 Seattle Genetics
12.14 Tocris Bioscience
Figure 1-1: Structure of Microtubule
Figure 1-2: Types of Tubulin Inhibitors for Cancer Treatment
Figure 3-1: Pathways for the Development of Cancer by Tubulin Alterations
Figure 3-2: Post Translational Modifications in Tubulin Structure
Figure 3-3: Structural Representation of Microtubule Associated Proteins
Figure 3-4: Tubulin Response to Cytoskeleton Stress
Figure 5-1: Docetaxel Drug Patent Approval and Expiry Year
Figure 5-2: Docetaxel Drug – Available Concentrations mg/ml
Figure 5-3: Docetaxel: Average Dosage Analysis in Breast Cancer Therapy (mg/m2)
Figure 5-4: Cost of Docetaxel Drug for the Concentration of 10 mg/ml, for 2 Milliliters, 8 Milliliters and 16 Milliliters, Respectively (US$), 2017
Figure 5-5: Cost of Docetaxel Drug for the Concentration of 20 mg/ml, for 1 Milliliters, 4 Milliliters, 8 Milliliters and 10 Milliliters, Respectively (US$), 2017
Figure 5-6: Cost of Docetaxel Drug for the Concentration of 40 mg/ml, for 0.5 Milliliters, and 2 Milliliters, Respectively (US$), 2017
Figure 5-7: Docetaxel Average Breast Cancer Treatment Cost (US$/Cycle), 2017
Figure 5-8: Docetaxel Average Lung Cancer Therapy Cost Analysis (US$/Cycle), 2018
Figure 5-9: Trastuzumab Emtansine Patent Approval and Expiry Year
Figure 5-10: Trastuzumab Emtansine: Average Dosage Analysis (mg/Dose)
Figure 5-11: Available Different Concentrations of Trastuzumab Emtansine (mg)
Figure 5-12: Trastuzumab Emtansine Price by Concentration (US$), 2017
Figure 5-13: Trastuzumab Emtansine: Vials Used in Metastatic Breast Cancer Treatment (By Number)
Figure 5-14: Trastuzumab Emtansine: Average Treatment Cost Analysis (US$), 2017
Figure 5-15: Abraxane: Patent Approval Year for Various Cancer Indications and Expiration Year
Figure 5-16: Abraxane Dosage Analysis by Indication (mg/m2)
Figure 5-17: Cost of Abraxane Intravenous Solution of 100 mg, US$
Figure 5-18: Abraxane: Cancer Treatment Cost Analysis per Cycle (US$), 2017
Figure 5-19: Brentuximab Vedotin Patent Approval and Expiry Years in US
Figure 5-20: Brentuximab Vedotin Patent Approval and Expiry Years in Europe
Figure 5-21: Price of Brentuximab Vedotin Drug for Per Vial of 50 mg and For 7 Cycles Treatment, (US$), 2017
Figure 5-22: US – Brenuximab Vedotin Price Analysis, (US$), 2017
Figure 5-23: US – Brenuximab Vedotin Treatment Expenditure (US$), 2014
Figure 5-24: US – Brenuximab Vedotin Treatment Cost (US$), 2017
Figure 5 25: Cabazitaxel: Price of Drug per Cycle in US$ and Patent Expiration Year
Figure 5-26: Cost of Jevtana Intravenous Solution and Per Unit Cost, US$, 2017
Figure 6-1: Global Sales of Docetaxel Drug (US$ Million), 2015 and 2016
Figure 6-2: Global -Trastuzumab Emtansine Sales Revenue, US$ Millions, 2013 and 2016
Figure 6-3: Global – Abraxane Sales US$ Million, 2014-2017*
Figure 6-4: Global – Brenuximab Vedotin Sales (US$ Million), 2014-2017
Figure 6-5: Global – Blinatumumab Half Yearly Sales (US$ Million), 2015-2017
Figure 6-6: Global – Sales of Cabazitaxel Drug, US$ million, 2015 andndash; 2017*
Figure 7-1: Global – Cancer Tubulin Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 7-2: Global – Cancer Tubulin Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 7-3: Global – Cancer Tubulin Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 7-4: Global – Cancer Tubulin Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 10-1: Favorable Market Parameters for Tubulin Inhibitors Development
Figure 10-2: Challenges to the Market Growth of Tubulin Inhibitors
Table 3-1: Clinical Studies of Tubulin Isotype in Drug Resistance
Table 5-1: Trastuzumab Emtansine Price Analysis
Table 5-2: Efficacy Results of Brentuximab Vedotin in Hodgkin Lymphoma Patients
Your information will never be shared with any third party.